LY2127399 + Placebo every 2 weeks + Placebo every 4 weeks
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Systemic Lupus Erythematosus
Conditions
Systemic Lupus Erythematosus, Connective Tissue Disease, Autoimmune Disease
Trial Timeline
Jan 1, 2011 → Mar 1, 2015
NCT ID
NCT01205438About LY2127399 + Placebo every 2 weeks + Placebo every 4 weeks
LY2127399 + Placebo every 2 weeks + Placebo every 4 weeks is a phase 3 stage product being developed by Eli Lilly for Systemic Lupus Erythematosus. The current trial status is completed. This product is registered under clinical trial identifier NCT01205438. Target conditions include Systemic Lupus Erythematosus, Connective Tissue Disease, Autoimmune Disease.
What happened to similar drugs?
10 of 20 similar drugs in Systemic Lupus Erythematosus were approved
Approved (10) Terminated (4) Active (7)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01205438 | Phase 3 | Completed |
Competing Products
20 competing products in Systemic Lupus Erythematosus
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Tabalumab Auto-Injector + Tabalumab Prefilled Syringe | Eli Lilly | Phase 3 | 32 |
| Baricitinib + Placebo | Eli Lilly | Phase 2 | 35 |
| MRA(Tocilizumab) + placebo | Chugai Pharmaceutical | Phase 3 | 40 |
| MRA(Tocilizumab) | Chugai Pharmaceutical | Phase 3 | 40 |
| MRA(Tocilizumab) | Chugai Pharmaceutical | Phase 3 | 40 |
| DS-7011a + Placebo | Daiichi Sankyo | Phase 1 | 29 |
| DS-7011a + Placebo | Daiichi Sankyo | Phase 1/2 | 32 |
| Bocidelpar + Placebo | Astellas Pharma | Phase 1 | 21 |
| Parenteral micafungin application + Other parenteral antifungal drugs | Astellas Pharma | Pre-clinical | 26 |
| Micafungin | Astellas Pharma | Phase 2 | 35 |
| E6742 | Eisai | Phase 1/2 | 32 |
| KHK4827 | Kyowa Kirin | Phase 1 | 29 |
| KHK4827 + Placebo | Kyowa Kirin | Phase 3 | 40 |
| Baricitinib + Placebo | Eli Lilly | Phase 3 | 40 |
| Baricitinib + Cyclophosphamide | Eli Lilly | Approved | 47 |
| Baricitinib + Placebo | Eli Lilly | Phase 3 | 32 |
| LY2127399 + Placebo every 2 weeks + Placebo every 4 weeks + Standard of Care | Eli Lilly | Phase 3 | 40 |
| LY3361237 + Placebo | Eli Lilly | Phase 2 | 27 |
| LY2127399 + Placebo | Eli Lilly | Phase 3 | 32 |
| LY3361237 + Placebo | Eli Lilly | Phase 1 | 29 |